Burkina Faso vs Lesotho: Average cost of multi drug-resistant tuberculosis treatment
Burkina Faso
159 constant 2022 US$
in 2024
Lesotho
81 constant 2022 US$
in 2024
Burkina Faso rank
91st
Lesotho rank
92nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Burkina Faso
- Lesotho
How they compare
Burkina Faso currently reports 159 constant 2022 US$ against 81 constant 2022 US$ in Lesotho, a difference of 78 constant 2022 US$.
That makes Burkina Faso's figure about 2.0 times Lesotho's.
The two have swapped places 1 time across 6 shared years of data; in 2018 it was Lesotho ahead.
Burkina Faso ranks 91st and Lesotho ranks 92nd of 92 countries.
Lesotho has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burkina Faso | Lesotho | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 446.5 constant 2022 US$ | 3,016 constant 2022 US$ | 2,569 constant 2022 US$ | Lesotho |
| 2020s | 753 constant 2022 US$ | 2,762 constant 2022 US$ | 2,009 constant 2022 US$ | Lesotho |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burkina Faso or Lesotho?
- Burkina Faso, at 159 constant 2022 US$ against 81 constant 2022 US$ in Lesotho as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burkina Faso and Lesotho?
- 78 constant 2022 US$, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Lesotho?
- 6 years are reported by both, from 2018 to 2024.
- How do Burkina Faso and Lesotho rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burkina Faso ranks 91st and Lesotho ranks 92nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.